The increase in risk was small approximately three to four additional cases per 10,000 patients treated with GLP-1s over 18 months, but clinicians and patients should be aware of this potential association. Researchers said while the risk is low, the rising use of GLP-1s in patients with and without Type 2 diabetes warrants special attention to medication safety
Enhanced detoxification, boosted immune function, and overall well-being are additional advantages that users may experience
Two participants (0.1%) prematurely discontinued the trial product because of COVID-19 infection, and three participants (0.2%) prematurely discontinued the trial product because of disruption caused by the COVID-19 pandemic
This customized approach ensures that your treatment is aligned with your unique needs, helping you achieve sustainable weight loss while addressing any underlying factors that could impact your progress
Pyruvate cycle increases aminoglycoside efficacy and provides respiratory energy in bacteria
